Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIO-TECHNE Corp Director's Dealing 2018

Jun 8, 2018

30718_dirs_2018-06-08_431a2f37-93b9-45eb-a38a-3106679d6d3d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2018-06-07

Reporting Person: Kummeth Charles R. (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-06-07 Common Stock S 8000.00 $160.00 Disposed 76472.00 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Restricted Stock Unit $ Common Stock (17283.00) 17283.00 Direct
Restricted Stock Unit $ Common Stock (24979.00) 24979.00 Direct
Restricted Stock Unit $ Common Stock (21291.00) 21291.00 Direct
Stock Option (Right to Buy) $108.49 2022-08-07 Common Stock (79517.00) 79517.00 Direct
Stock Option (Right to Buy) $108.49 2022-08-07 Common Stock (119275.00) 119275.00 Direct
Stock Option (Right to Buy) $106.59 2023-08-18 Common Stock (102779.00) 102779.00 Direct
Stock Option (Right to Buy) $106.59 2023-08-18 Common Stock (154169.00) 154169.00 Direct
Stock Option (Right to Buy) $86.25 2021-04-01 Common Stock (46316.00) 46316.00 Direct
Stock Option (Right to Buy) $67.46 2020-04-01 Common Stock (65000.00) 65000.00 Direct
Stock Option (Right to Buy) $67.46 2020-04-01 Common Stock (50000.00) 50000.00 Direct
Stock Options (Right to buy) $125.05 2024-08-09 Common Stock (117342.00) 117342.00 Direct
Stock Options (Right to buy) $125.05 2024-08-09 Common Stock (78228.00) 78228.00 Direct
Stock Options (Right to buy) $94.35 2021-08-12 Common Stock (66849.00) 66849.00 Direct

Footnotes

F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2018.

F10: Fully exercisable

F11: Vests 19,557 each on 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021

F2: Includes (i) 10,203 shares for which the risk of forfeiture will lapse pursuant to achievement of performance goals; (ii) 3,841 shares for which the risks of forfeiture will lapse on August 7, 2018; and (iii) 11,102 shares for which the risks of forfeiture will lapse with respect to 5,551 shares on each of August 18, 2018 and August 18, 2019; and (iv) 4,731 shares each which risks of forfeiture will lapse on August 9, 2018 and August 9, 2019; and (v) 4,732 shares for which risks of forfeiture will lapse on August 9, 2020

F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

F4: Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F5: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F6: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F7: 19,879 shares vest on each of August 7, 2016, August 7, 2017 and August 7, 2018 and 19,880 shares vest on August 7, 2019.

F8: Vests 25,695 shares on each of 8/18/17, 8/18/18, and 8/18/19 and 25,694 shares on 8/18/20.

F9: The option will vest pursuant to the following schedule: 5,790 shares on October 1, 2014, 965 shares on the first day of the month for the period beginning November 1, 2014 and ending March 1, 2018, and 961 shares on April 1, 2018.